Literature DB >> 1846070

Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid.

M J Tisdale1, S A Beck.   

Abstract

Stimulation of lipolysis in murine adipocytes in response to a lipid-mobilizing factor produced by a cachexia-inducing murine adenocarcinoma was inhibited by eicosapentaenoic acid (EPA) with a Ki value of 104 microM. The inhibitory effect was strictly structurally specific, since other related fatty acids of both the (n-3) and (n-6) series were ineffective as inhibitors of the lipolytic process. Induction of lipolysis by both salbutamol and ACTH was also inhibited by EPA, suggesting that the effect is exerted on a step central to the process of lipolysis. Lipolysis induced with the tumour lipid-mobilizing factor was associated with a prolonged elevation of the intracellular level of cyclic AMP in adipocytes, in contrast with ACTH and salbutamol. The elevation of adipocyte cyclic AMP in response to the tumour lipid-mobilizing factor and lipolytic hormones was inhibited by EPA. In vivo, administration of pure EPA to weight losing mice bearing the MAC16 adenocarcinoma completely prevented weight loss and tumour growth rate. In contrast both the other (n-3) fatty acid present in fish oil, docosahexaenoic acid (DHA), and linoleic acid were ineffective in inhibiting weight loss or the growth of the MAC16 tumour. This suggests that inhibition of tumour lipolytic activity accounts for the anticachectic effect of EPA, and that a correlation may exist between the inhibition of cachexia and the inhibition of tumour growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846070     DOI: 10.1016/0006-2952(91)90016-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation.

Authors:  L Klieveri; O Fehres; P Griffini; C J Van Noorden; W M Frederiks
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Modulation of human hepatocyte acute phase protein production in vitro by n-3 and n-6 polyunsaturated fatty acids.

Authors:  S J Wigmore; K C Fearon; J A Ross
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

3.  Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats.

Authors:  T G Atkinson; H J Barker; K A Meckling-Gill
Journal:  Lipids       Date:  1997-03       Impact factor: 1.880

Review 4.  Nutritional prehabilitation in head and neck cancer: a systematic review.

Authors:  Linda A Cantwell; Emer Fahy; Emily R Walters; Joanne M Patterson
Journal:  Support Care Cancer       Date:  2022-08-01       Impact factor: 3.359

5.  Eicosapentaenoic acid inhibits cell growth and triacylglycerol secretion in McA-RH7777 rat hepatoma cultures.

Authors:  J C Fox; R V Hay
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

6.  Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors.

Authors:  P C Dagnelie; J D Bell; S C Williams; T E Bates; P D Abel; C S Foster
Journal:  Lipids       Date:  1994-03       Impact factor: 1.880

7.  Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model.

Authors:  H K van Halteren; G P A Bongaerts; C A M Verhagen; Y J L Kamm; J L Willems; G J Grutters; J P Koopman; D J Th Wagener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-27       Impact factor: 4.553

Review 8.  Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients.

Authors:  Todd T Brown; Danielle L Zelnik; Adrian S Dobs
Journal:  Int J Gastrointest Cancer       Date:  2003

9.  Lipid metabolism in cancer cachexia.

Authors:  H D Mulligan; S A Beck; M J Tisdale
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 10.  The role of triglyceride lipases in cancer associated cachexia.

Authors:  Suman K Das; Gerald Hoefler
Journal:  Trends Mol Med       Date:  2013-03-14       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.